Full Text AA-94-001 BIOMEDICAL AND BEHAVIORAL RESEARCH ON ALCOHOL AND WOMEN NIH GUIDE, Volume 22, Number 36, October 8, 1993 RFA: AA-94-001 P.T. 34, II Keywords: Alcohol/Alcoholism Behavioral/Social Studies/Service Social Psychology Disease Prevention+ National Institute on Alcohol Abuse and Alcoholism Application Receipt Date: January 12, 1994 PURPOSE The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is seeking research grant applications to study the health, biological, behavioral, psychosocial, and other consequences of alcohol consumption on women; identify risk and protective factors; and develop more effective identification, treatment, and prevention strategies and programs. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Request for Applications (RFA), Biomedical and Behavioral Research on Alcohol and Women, is related to the priority areas of alcohol abuse reduction and alcoholism treatment. Potential applicants may obtain a copy of Healthy People 2000 (Full Report: Stock No. 017-001-00474-0, or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY Applications may be submitted by domestic and foreign, public and private, non-profit and for-profit organizations, such as universities, colleges, hospitals, research institutes and organizations, units of State and local governments, and eligible agencies of the Federal government. Women and minority investigators are encouraged to apply. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) Awards (R29). MECHANISMS OF SUPPORT Research support may be obtained through applications for a regular research grant (R01) or FIRST Award (R29). Applicants for R01s may request support for up to five years. In FY 1992, the average total cost per year for new R01s funded by NIAAA was approximately $200,000. Because the nature and scope of the research proposed in response to this RFA may vary, it is anticipated that the size of an award will vary also. FIRST Award applications must be for five years. Total direct costs for the five-year period may not exceed $350,000 or $100,000 in any one budget period. FIRST Awards cannot be renewed, but grantees may apply for R01 support to continue research on the same topics. Applicants for FIRST Awards may obtain copies of the FIRST program announcement from the National Clearinghouse for Alcohol and Drug Information, P.O. Box 2345, Rockville, Maryland 20852, telephone: 301-468-2600 or 1-800-729-6686. Program project grants (P01) will not be accepted for this RFA. Applicants may submit Investigator-Initiated Interactive Research Project Grants (IRPG). Interactive Research Project Grants require the coordinated submission of related research project grant (R01) and, to a limited extent FIRST Award (R29) applications from investigators who wish to collaborate on research, but do not require extensive shared physical resources. These applications must share a common theme and describe the objectives and scientific importance of the interchange of, for example, ideas, data, and materials among the collaborating investigators. A minimum of two independent investigators with related research objectives may submit concurrent, collaborative, cross-referenced individual R01 and R29 applications. Applicants may be from one or several institutions. Further information on the IRPG mechanism is available in program announcement PA-93-078, NIH Guide for Grants and Contracts, Vol. 22, No. 16, April 23, 1993. FUNDS AVAILABLE It is estimated that up to two million dollars in total will be available for approximately 8 to 10 grants under this RFA in FY 1994. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NIAAA, the award of grants pursuant to this RFA is also contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES The objective of this RFA is to foster research that will ultimately lead to the reduction of alcohol abuse, dependence and consequences among women. Such research may address the etiologic factors (including cellular and molecular mechanisms, unique neurobiological, hormonal, and behavioral vulnerabilities), incidence, prevalence, and natural history of alcohol-related medical consequences; identify risk factors and markers of risk that predict development of alcohol dependence or enhanced vulnerability to specific alcohol-induced organ or tissue damage; examine gender differences in the interaction of genetic, individual, and environmental factors; document barriers to diagnosis, intervention, and treatment specific to women; and develop and test more effective intervention strategies for the prevention and treatment of alcohol-related problems among women across the lifespan from childhood to old age. Background Fewer women than men drink and, on the whole, women who drink consume less alcohol and have fewer alcohol-related problems than men. Yet, among the heaviest drinkers, women equal or surpass men in the number of problems that result from their drinking. The interval between onset of drinking-related problems and entry into treatment appears to be shorter for women. Women are known to be more susceptible to alcohol induced liver damage than are men--developing severe liver disease especially alcoholic hepatitis and cirrhosis, with shorter durations of alcohol use and lower levels of consumption. The exact mechanism of this enhanced susceptibility remains to be elucidated. Gender-specific vulnerability to other alcohol-induced organ/tissue damage also requires investigation. Breast cancer is the second leading cause of cancer death among women in the United States today. Current epidemiologic evidence suggests that alcohol consumption, even at low levels, may increase a woman's risk of breast cancer. Further research is required in all aspects of this area. Clearly gender differences exist in the human body's responses to alcohol consumption. Alcohol research is now at the point where elucidation of such gender differences and their implications for prevention, intervention and treatment is needed. Areas of Research Interest The following list of topics is intended only to illustrate NIAAA interests; topics not mentioned are not necessarily excluded from consideration. Areas include studies of the natural history, biological mechanisms, incidence and prevalence of alcohol use, abuse, dependence, and consequences among women and female animals, specifically: o Identification of cellular and molecular mechanisms related to the apparent increased vulnerability of women to alcohol-induced liver damage including possible gender differences in rates of alcohol metabolism and acetaldehyde production; differential vulnerability to hepatic hypoxia due to lower hematocrit; possible differences in glycoconjugate metabolism or in alcohol's effects on the integrity of glycoproteins and glycolipids. o Identification of mechanisms by which alcohol contributes to the increased risk of hemorrhagic stroke in women, including interactions between alcohol and oral contraceptives as well as other medications, and gender differences and mechanisms in other cardiac pathology. o Evaluation of the effects of acute and chronic alcohol consumption on bone and mineral metabolism in pre- and postmenopausal women, interaction between alcohol and hormones involved in calcium metabolism, impact of alcohol consumption on osteoporosis in women. o Studies of the relationship of alcohol consumption to an increased risk of breast cancer including mechanisms of carcinogenesis, estrogen receptor status, hormone (endogenous and exogenous) interactions. o Studies of the impact of alcohol consumption on the female reproductive system including elucidation of the mechanisms by which alcohol induces amenorrhea and infertility, and impact of alcohol consumption on the maturation of the reproductive system in the adolescent female. o Studies of gender-specific interactions between alcohol and other medications, both prescription and over the counter; and developing and testing interventions that can prevent or reduce the risk of such interactions among women, e.g., educational strategies, counseling by health professionals. o Studies of alcohol's effects on the hypothalamic/ pituitary/adrenal axis in women as well as on that of children exposed to alcohol in utero, and the role of these effects in alcohol-seeking behavior. o Studies of the relationship of gender-specific comorbidity of psychopathology and alcoholism such as the disproportional prevalence of depression among women alcoholics. o Studies of gender differences in the patterns of voluntary alcohol intake, the extent to which they are under genetic control, the role of hormones (including neurosteroids), and the role of neurotransmitter and peptide systems. o Studies of the relationship between alcohol consumption and other dietary components, gender differences in the utilization of alcohol calories, the regulation of food intake and satiety in relation to craving for alcohol and regulation of alcohol intake. o Studies to ascertain whether or not gender-specific alcohol interventions improve treatment efficacy for women, determination of barriers to identification, diagnosis, and treatment for women. o Development of pharmacotherapies that provide more effective medication for women. o Identification of genetic or biological markers or laboratory procedures that are specific for diagnosis of alcohol dependence or chronic alcohol consumption in women or that show gender differences. o Studies to determine whether or not women are differentially susceptible to alcoholic cardiomyopathy and possible etiologic factors and mechanisms, other gender differences in the relationship of alcohol to other cardiac conditions, pancreatic diseases, and gastritis. o Studies utilizing modern technology such as imaging techniques to examine gender differences in alcohol-induced organ pathology. o Studies of relationships between alcohol use and violence toward women and by women; possible increased vulnerability of women with alcohol problems to engage in violence; childhood physical/sexual abuse as a contributory factor to alcohol dependence in women; and the role of posttraumatic stress disorder in the development of alcohol dependence. o Developing and testing interventions to prevent or reduce alcohol- related domestic violence, child abuse, and rape by strangers, dates, and intimates. o Studies of the linkage between alcohol use and unsafe sexual practices among both adolescent and adult women, especially studies of risk perception, risk taking and excusatory behavior in alcohol use and HIV exposure, and studies that test possible prevention strategies to reduce the risk of HIV exposure in the context of alcohol use. o Development and testing of gender-sensitive treatment strategies, including consideration of physiological and behavioral differences. o Development and testing of gender-sensitive prevention strategies (educational and environmental) that address exposure of girls and women to risky drinking environments and social interactions involving alcohol, e.g., riding with drunk drivers. o Studies of the influence of women's roles in the workplace and home, the impact of dual roles on their drinking behavior, and developing and testing preventive interventions that address role- related alcohol problems. o Developing and testing preventive interventions that specifically address drinking practices and motivations of adolescent girls, including self-image, sexuality, peer influences, sex roles, and social deviancy. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS Applications for NIH grants and cooperative agreements are required to include both women and minorities in study populations for clinical research, unless compelling scientific or other justification for not including either women or minorities is provided. This requirement is intended to ensure that research findings will be of benefit to all persons at risk of the disease, disorder, or condition under study. For the purpose of these policies, clinical research involves human studies of etiology, treatment, diagnosis, prevention, or epidemiology of diseases, disorders or conditions, including but not limited to clinical trials; and minorities include U.S. racial/ethnic minority populations (specifically: American Indians or Alaskan Natives, Asian/Pacific Islanders, Blacks, and Hispanics). NIH recognizes that it may not be feasible or appropriate in all clinical research projects to include representation of the full array of U.S. racial/ethnic minority populations. However, applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. Applications must include a description of the composition of the proposed study population by gender and racial/ethnic group, and the rationale for the numbers and kinds of people selected to participate. This information must be included in the form PHS 398 in Sections 1-4 of the Research Plan and summarized in Section 5, Human Subjects. Applications should incorporate in their study design gender and/or minority representation appropriate to the scientific objectives of the work proposed. If representation of women or minorities in sufficient numbers to permit assessment of differential effects is not feasible or is not appropriate, the reasons for this must be explained and justified. The rationale may relate to the purpose of the research, the health of the subjects, or other compelling circumstances (e.g., if in the only study population available, there is a disproportionate representation in terms of age distribution, risk factors, incidence/prevalence, etc., of one gender or minority/majority group). If the required information is not contained within the application, the review will be deferred until it is complete. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If gender and/or minority representation/ justification are judged to be inadequate, reviewers will consider this as a deficiency in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants that do not comply with these policies. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research; from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301-710-0267; and from the NIAAA program administrator listed under INQUIRIES. The RFA label available in the PHS (rev. 9/91) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. Page limits and limits on size of type are strictly enforced. Applicants for FIRST Awards (R29) are reminded that such applications must include three letters of reference. Non-conforming applications will be returned without being reviewed. Applicants from institutions that have a General Clinical Research Center (GCRC), funded by the NIH Division of Research Resources, may wish to identify the Center as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC program director or Principal Investigator should be included in the application material. The signed original, including the checklist, and three signed, legible copies of the completed application must be sent to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to: Mark Green, Ph.D. Extramural Project Review Branch National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard Rockville, MD 20892 Telephone: (301) 443-4375 FAX: (301) 443-6077 Applications must be received by January 12, 1994. If an application is received after that date, it will be assigned to the next review cycle and will compete with all investigator-initiated research grant applications. The Division of Research Grants (DRG) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS The Division of Research Grants, NIH, serves as a central point for receipt of applications for most discretionary PHS grant programs. Upon receipt, applications will be reviewed for completeness by DRG and responsiveness by the NIAAA. Incomplete applications will be returned to the applicant without further consideration. If the application is not responsive to the RFA, NIAAA staff will contact the applicant to determine whether to return the application to the applicant or submit it for review in competition with unsolicited applications at the next review cycle. Applications may be triaged by an NIAAA peer review group on the basis of relative competitiveness. The NIH will withdraw from further competition those applications judged to be non-competitive for award and notify the applicant Principal Investigator and institutional official. Those applications judged to be competitive will undergo further scientific merit review. Those applications that are complete and responsive will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate peer review group convened by the NIAAA. The second level of review will be provided by the National Advisory Council on Alcohol Abuse and Alcoholism. Review Criteria Criteria to be used in the scientific and technical merit review of alcohol research grant applications will include: 1. The scientific, technical, or medical significance and originality of the proposed research. 2. The appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research. 3. The adequacy of the qualifications (including level of education and training) and relevant research experience of the Principal Investigator and key research personnel. 4. The availability of adequate facilities, general environment for the conduct of the proposed research, other resources, and collaborative arrangements necessary for the research. 5. The reasonableness of budget estimates and duration for the proposed research. 6. Where applicable, the adequacy of procedures to protect or minimize effects on animal and human subjects and the environment. 7. Conformance of the application to the NIH policy on inclusion of women and minorities in study populations. Research grant applications will be reviewed based on standard criteria for scientific and technical merit for regular research grants (R01). The review criteria for FIRST Awards (R29) are contained in the FIRST program announcement. AWARD CRITERIA Applications recommended for approval by the National Advisory Council on Alcohol Abuse and Alcoholism will be considered for funding on the basis of the overall scientific and technical merit of the application as determined by peer review, NIAAA programmatic needs and balance, and the availability of funds. INQUIRIES Potential applicants are encouraged to seek preapplication consultation and may contact the individuals listed below for consultation in preparing an application under this RFA. Direct inquiries regarding programmatic issues to: Mary C. Dufour, M.D., M.P.H. Division of Biometry and Epidemiology National Institute on Alcohol Abuse and Alcoholism 5600 Fishers Lane, Room 14C-26 Rockville, MD 20857 Telephone: (301) 443-4897 FAX: (301) 443-8614 Direct inquiries regarding fiscal matters to: Elsie Fleming Office of Planning and Resource Management National Institute on Alcohol Abuse and Alcoholism 5600 Fishers Lane, Room 16-86 Rockville, MD 20857 Telephone: (301) 443-4703 FAX: (301) 443-3891 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance, No. 93.273. Awards are made under the authorization of the Public Health Service Act, Sections 301 and 464H, and administered under the PHS policies and Federal Regulations at Title 42 CFR Part 52, "Grants for Research Projects," and Title 45 CFR Parts 74 and 92, "Administration of Grants and 45 CFR Part 46, "Protections of Human Subjects." This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||